Acorda Therapeutics (NASDAQ: ACOR) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
Insider & Institutional Ownership
4.2% of Pluristem Therapeutics shares are owned by institutional investors. 7.9% of Acorda Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Pluristem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Acorda Therapeutics and Pluristem Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Acorda Therapeutics currently has a consensus price target of $21.83, suggesting a potential downside of 5.07%. Pluristem Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 227.87%. Given Pluristem Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Pluristem Therapeutics is more favorable than Acorda Therapeutics.
Valuation and Earnings
This table compares Acorda Therapeutics and Pluristem Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Acorda Therapeutics||$588.29 million||1.83||-$223.35 million||$1.04||22.12|
|Pluristem Therapeutics||$2.85 million||47.46||-$27.81 million||($0.32)||-3.81|
Pluristem Therapeutics has lower revenue, but higher earnings than Acorda Therapeutics. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Acorda Therapeutics and Pluristem Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Acorda Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Pluristem Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS. The Company’s product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.